Research programme: HSC derived CAR engineered invariant NKT cells therapies - Appia Bio
Latest Information Update: 16 Oct 2023
At a glance
- Originator Appia Bio
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Haematopoietic stem cells therapies; Immunotherapies; NKT cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer T cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Multiple myeloma
Most Recent Events
- 29 Sep 2023 Appia Bio has patent protection for its ACUA platform prior to September 2023 (Appia Bio website; September 2023)
- 29 Sep 2023 Early research in Multiple myeloma in USA (Parenteral)